Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
GM-1020 by Gilgamesh Pharmaceuticals for Major Depressive Disorder: Likelihood of Approval
GM-1020 is under clinical development by Gilgamesh Pharmaceuticals and currently in Phase II for Major Depressive Disorder. According to GlobalData,...